DOCSLIB.ORG

Twenty-Second Meeting of the European Neurological Society 9–12 June, 2012 Prague, Czech Republic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Twenty-Second Meeting of the European Neurological Society 9–12 June, 2012 Prague, Czech Republic J Neurol (2012) 259 (Suppl 1):S1–S236 DOI 10.1007/s00415-012-6524-4 ABSTRACTS Twenty-second Meeting of the European Neurological Society 9–12 June, 2012 Prague, Czech Republic Symposia and Free Communications The abstracts have been reviewed by: O. Abramsky, C. Angelini, P. Annunziata, F. Antonaci, Z. Argov, A. Arzimanoglou, T. Back, O. Bajenaru, E. Bartels, J. Bednarˇik, P.D. Berlit, K. Bhatia, P. Boon, T. Brandt, B. Brochet, M.J. Brodie, C. Caltagirone, P. Canha˜o, H. Cock, C. Colosimo, G. Comi, L. Cunha, M. de Carvalho, J. de Keyser, J.L. De Reuck, M. de Visser, L. Deecke, R. Dengler, S. Di Donato, M. Dieterich, V. Dietz, C. Elger, M. Eraksoy, F. Fazekas, J. Ferro, M. Filippi, D. Galimberti, T. Gasser, A. Grau, W. Grisold, U. Gschwandtner, O. Hardiman, H.P. Hartung, W. Heide, C. Helmchen, G. Ickenstein, R. Jech, P. Kanˇovsky´, P. Kalvach, L. Kappos, A. Keyser, B. Kieseier, T. Klopstock, C. Krarup, G. Lammers, S. Laureys, G. Mayer, S.I. Mellgren, G. Meola, R. Milo, I. Milonas, X. Montalban, O. Nascimento, E. Nobile-Orazio, L. Nobili, W.H. Oertel, M. Onofrj, A. Palla, S.G. Papageorgiou, D. Pareyson, Y. Parman, M. Partinen, H.W. Pfister, W. Poewe, D. Pohl, P. Portegies, H. Reichmann, P.F. Reyes, M.A. Rocca, A. Rossetti, P.M. Rossini, J. Roth, E. Ru˚zˇicˇka, G. Said, M. Sandberg-Wollheim, J. Santamaria, E. Scarpini, N. Schaeren-Wiemers, B. Schalke, P. Schestatsky, E. Schmutzhard, J. Schoenen, A. Sena, V. Silani, A. Siva, P. Soelberg-Sørensen, R. Soffietti, C. Sommer, K. Sˇonka, A. Steck, G. Stoll, A. Sumner, E. Tolosa, A. Toscano, K.V. Toyka, H. Tumani, J. Valls-Sole´, M. Veloso, A. Vendelho, P. Vermersch, M.J. Viana Baptista, R.D. Voltz, J. Vymazal, M. Weller We would like to thank the reviewers for their precious help and assistance. 123 S2 J Neurol (2012) 259 (Suppl 1):S1–S236 Presidential Symposium POSTER SESSIONS Parkinson Syndrome: an everlasting challenge 45–47 Poster session 1 Symposia Multiple sclerosis: disease modifying treatment I P336–P360 Joint ENS-CNS Symposium—Audio & video media in evaluation of Cerebrovascular disorders I P361–P380 movement disorders 100–104 Neuro-imaging P381–P406 Symposium—Stem cells ready for clinical practice 106–109 Movement disorders P407–P424 Symposium—Neuro-imaging and early diagnosis of General neurology P425–P451 neurological diseases 110–113 Preclinical biology P452–P456 Symposium—MS and acquired demyelinating disorders 143–146 Symposium—Neurology and sleep-wake disorders 147–150 Poster session 2 Symposium—Knowledge exchange programme in neurology between European and Indian Clinicians 158–161 Multiple sclerosis: disease modifying treatment II P457–P482 Cerebrovascular disorders II P483–P498 Peripheral neuropathy P499–P524 FREE COMMUNICATIONS Dementia I P525–P541 Motor neuron disease P542–P555 General neurology II P556–P570 Oral sessions Child neurology P571–P578 Session 1: Multiple sclerosis: Poster session 3 Imaging/neurophysiology O192–O197 Session 2: Epilepsy I O198–O203 Multiple sclerosis: variants and symptomatic treatment P579–P602 Session 3: Movement disorders I O204–O209 Cerebrovascular disorders III P603–P619 Session 4: Neuro-ophthalmology O210–O215 Pain and headache P620–P644 Session 5: Multiple sclerosis II O216–O221 Dementia II P645–P661 Session 6: Epilepsy II O222–O227 Epilepsy P662–P677 Session 7: Movement disorders II O228–O233 Neurogenetics P678–P692 Session 8: Imaging O234–O239 Clinical neurophysiology P693–P700 Session 9: Movement disorders III O240–O245 Session 10: Sleep disorders O246–O251 Poster session 4 Session 11: General neurology O252–O256 Session 12: Multiple sclerosis III O258–O263 Multiple sclerosis: miscellaneous P701–P729 Session 13: Cerebrovascular disorders I O264–O269 Cerebrovascular disorders IV P730–P752 Session 14: Neuromuscular disorders O270–O275 Muscle disorders P753–P768 Session 15: Child neurology O276–O281 Neurorehabilitation P769–P780 Session 16: Neuro-oncology O282–O287 Neuro-oncology P781–P790 Session 17: Multiple sclerosis IV O288–O293 Infection P791–P799 Session 18: Cerebrovascular disorders II O294–O299 Neuro-ophthalmology P800–P805 Session 19: Motor neuron disease O300–O305 Session 20: Infection O306–O311 Session 21: Neurorehabilitation O312–O317 Session 22: Clinical neurophysiology O318–O323 Session 23: Dementia O324–O329 Session 24: Pain and headache O330–O335 123 J Neurol (2012) 259 (Suppl 1):S1–S236 S3 Presidential Symposium short half-life drug L-Dopa is now seen as the main factor for the development of motor response oscillations and drug-induced dy- skinesias associated with this type of treatment. Improving the Parkinson Syndrome: an everlasting challenge pharmacokinetics and mode of delivery of dopaminergic agents is therefore a key element of managing motor response oscillations. Standard approaches include adjunct COMT-inhibition and/or MAO- 45 B-inhibition with L-Dopa as well as the use of longer half-life non- Does early diagnosis lead to early treatment ergolinic dopamine agonists and their extended release formulations. of Parkinson’s disease? Continuous drug delivery using subcutaneous apomorphine infusions H. Reichmann or intrajejunal infusions of duodopa not only smooth out motor University of Dresden (Dresden, DE) fluctuations but also lead to reductions in pre-existing dyskinesias. Future developments of novel dopaminergic approaches to PD ther- We don’t know how long it takes from the onset of first clinical apy may also include intrapulmonary delivery with inhaler systems as symptoms of Parkinson’s disease (PD) to medical diagnosis. Until well as gene-therapeutic enhancement of local DA-production in the recently, no major interest has focused in these early stages, because it striatum. Currently amantadine is the only drug with proven efficacy is classically recommended to wait for prescribing treatments until to reduce levodopa dyskinesias, but several non-dopaminergic drugs disability occurs. Such views are changing, with novel concepts in the targeting glutamatergic receptors are being developed to broaden the natural history of early PD and new attempts to diagnose and treat the spectrum of antidyskinetic agents of PD. In addition, drugs targeting patients earlier than previously. glutamatergic, serotonergic, alphaadrenergic as well as adenosine- We know for many years that PD begins years before patients and A2a receptors are being developed and may be a promising approach doctors notice the first motor signs. There is increasing evidence that a to control levodopa-induced dyskinesias or motor fluctuations. variety of non-motor symptoms are common in PD patients before the Deep brain stimulation (DBS) targeting the STN or GPi are an onset of any motor sign. Such non-motor symptoms include hyposmia, established modality for the management of motor complications in REM sleep behaviour disorder, constipation, depression, problems in drug refractory patients. colour discrimination and sensory signs. It is now proposed that these Recent randomized trials have shown similar effects of STN and symptoms may characterize a ‘‘pre-motor’’ phase of PD. GPi stimulation and also that DBS improves quality-of-life of patients There is a growing debate to decide whether we should continue or with advanced PD. not to wait for ‘‘sufficient’’ disability before treating patients. The UK PD-LIFE study showed that immediate anti-Parkinsonian treatment maintained quality of life scores (PDQ-39) stable in early PD patients over 18 months, while scores deteriorated in those remaining 47 untreated. Moreover, the recent ADAGIO placebo-controlled study, Treatment of non-motor symptoms using the delayed-start design, showed that patients with early PD (5 months from diagnosis) randomized to receive rasagiline (1mg/day) P. Barone immediately (early-start group) had less worsening in UPDRS scores University of Salerno (Salerno, IT) after 18 months of follow-up than those receiving the same treatment Non-motor symptoms (NMSs) are common in Parkinson’s disease 9 months later (delayed-start group). Unfortunately, the PROUD (PD) and have recently gained relevance for their impact on prospective placebo-controlled delayed-start study with the dopamine patients’ quality of life (QoL) and their contribution to institution- agonist pramipexole did fail and showed no superiority for patients alization. Despite their impact, NMSs in PD are under-recognized in who were treated immediately after diagnosis. clinical practice and, consequently, undertreated. NMSs can present To avoid dyskinesia it is common practice to start with a dopamine at any stage of disease, including early and pre-motor phase of PD. agonist and due to the results of ADAGIO and previously TEMPO it The pathophysiology of NMSs is still poorly understood, and a may be well taken to add a MAO-B-inhibitor. dysfunction of both dopaminergic and non-dopaminergic systems A practical way would therefore be to start mildly impaired de contributes to their development. Recently the PRIAMO study novo patients with a MAO-B-inhibitor and those who are more described the prevalence of NMSs, their relevance for cognitive impaired with a dopamine agonist to add the other substance later. impairment and their overall impact on QoL in a large cohort of During the course of the disease levo-Dopa will be needed which Italian patients with PD. Most frequently reported NMSs were should be initiated in biologically old patients at the beginning of psychiatric, sleep, gastrointestinal, pain, fatigue and urinary. More- their PD disease. over patients who reported apathy, attention/memory deficit and Professor
Load more

Recommended publications
  • Supplementary Note ‐ Novel Genetic Loci for Atrial Fibrillation
    Supplementary Note ‐ Novel genetic loci for atrial fibrillation SUPPLEMENTARY NOTE Large‐scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation INDEX 1. Supplementary tables Supplementary Table 1. Baseline characteristics GWAS Supplementary Table 2. Baseline characteristics ExWAS Supplementary Table 3. Detailed description of the genes at novel atrial fibrillation loci Supplementary Table 4. Results from Asian ancestry SKAT gene based test Supplementary Table 5. Single variant association results for the variants that were analyzed in the two significant gene‐based tests for SH3PDX2A in the Asian ancestry group Supplementary Table 6. Results from ancestry‐specific GWAS meta‐analyses Supplementary Table 7. Results from European and Asian ancestry ExWAS meta‐ analyses Supplementary Table 8. Results from European incident atrial fibrillation GWAS meta‐ analysis Supplementary Table 9. Results from European prevalent atrial fibrillation GWAS meta‐ analysis Supplementary Table 10. Comparison of results for common variant loci between the AFGen Consortium combined ancestry analysis and the Biobank Japan study Supplementary Table 11. Comparison of results for common variant loci between the AFGen Consortium combined ancestry analysis and the UK Biobank study. Supplementary Table 12. Approximate and joint conditional analysis in European ancestry results identify 20 independent genetic loci associated with atrial fibrillation Supplementary Table 13. Overlap with atrial fibrillation risk factor GWAS loci Supplementary Table 14. Association between novel atrial fibrillation loci and stroke subtypes in the Neuro‐CHARGE Stroke Consortium Supplementary Note ‐ Novel genetic loci for atrial fibrillation Supplementary Table 15. Association between novel atrial fibrillation loci and stroke subtypes in the Metastroke Consortium Supplementary Table 16.
    [Show full text]
  • Annex 5. Data Sheets A. Office of Internal Oversight Services (OIOS)
    Annex 5. Data Sheets a. Office of Internal Oversight Services (OIOS) Anti-corruption Strategy OIOS, through independent, professional and timely audit, inspection, evaluation, monitoring and investigation activities, provides the United Nations management, the Secretary-General and the General Assembly with objective and useful information, advice and reports that support the achievement of organizational goals in the most cost-effective manner. As an agent of positive change, OIOS assists managers in promoting: 1. Accountability for the stewardship of resources 2. Efficiency and productivity 3. Cost-effective controls to ensure compliance with authority minimise waste and deter fraud and dishonesty. The Audit and Management Consulting Division (AMCD) is represented in Geneva and Nairobi. The Investigations Section is only represented in Nairobi. The other OIOS units, the Central Evaluation Unit and the Central Monitoring and Inspection Unit, do not have regional offices. Activities in the past Place Sectors Components Date Budget Coordinator Partners Progress of the investigation and action 02 Feb thereon to Determine Responsibility for the 1995 theft of US$3.9 million in UNOSOM II Investigation of allegations of irregularities 05 Apr and mismanagement in MINURSO 1995 Audit of the UNPROFOR personnel pilot 06 Jun project 1995 Audit report on the United Nations Access 30 Control System project Nov 1995 Strengthening the role of evaluation 04 Apr findings in programme design, delivery and 1996 policy directives Audit of procurement handled
    [Show full text]
  • For Peer Review Only
    BMJ Open BMJ Open: first published as 10.1136/bmjopen-2014-005276 on 7 November 2014. Downloaded from FAST Warning Signs in Younger Stroke Patients: Implications for Stroke Education Campaigns ForJournal: peerBMJ Open review only Manuscript ID: bmjopen-2014-005276 Article Type: Research Date Submitted by the Author: 17-Mar-2014 Complete List of Authors: Kaps, M; JustusLiebig Universit�t Giessen Grittner, Ulrike; Department of Biostatistics and Clinical Epidemiology, Charité- University Medicine Berlin, Germany, Tanislav, Christian; Justus Liebig University , Neurology Jungehuelsing, Gerhard; Charit� Berlin, Department of Neurology Tatlisumak, Turgut; Helsinki University Central Hospital, Department of Neurology Kessler, Christof; University Greifswald, Neurology Schmidt, Reinhold; Department of Neurology, University of Graz, Austria, Putaala, Jukka; University of Helsinki, Department of Neurological Sciences; Helsinki University Central Hospital, Department of Neurology Norrving, Bo; Lund University Hospital Rolfs, Arndt; University of Rostock, Department of Neurology <b>Primary Subject http://bmjopen.bmj.com/ Health services research Heading</b>: Cardiovascular medicine, Diagnostics, Epidemiology, Health services Secondary Subject Heading: research, Neurology Stroke < NEUROLOGY, HEALTH SERVICES ADMINISTRATION & Keywords: MANAGEMENT, EPIDEMIOLOGY, MEDICAL EDUCATION & TRAINING, NEUROLOGY on September 25, 2021 by guest. Protected copyright. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 1 of 25 BMJ Open BMJ
    [Show full text]
  • Genome-Wide Association Analysis of Young Onset Stroke Identifies a Locus on Chromosome 10Q25 Near HABP2
    Original Contribution Genome-Wide Association Analysis of Young Onset Stroke Identifies a Locus on Chromosome 10q25 Near HABP2 Yu-Ching Cheng, PhD; Tara M. Stanne, PhD; Anne-Katrin Giese, MD; Weang Kee Ho, PhD; Matthew Traylor, PhD; Philippe Amouyel, MD, PhD; Elizabeth G. Holliday, PhD; Rainer Malik, PhD; Huichun Xu, MD, PhD; Steven J. Kittner, MD; John W. Cole, MD; Jeffrey R. O’Connell, PhD; John Danesh, DPhil, FRCP; Asif Rasheed, MBBS; Wei Zhao, MSc; Stefan Engelter, MD; Caspar Grond-Ginsbach, PhD; Yoichiro Kamatani, MD, PhD; Mark Lathrop, PhD; Didier Leys, MD, PhD; Vincent Thijs, MD, PhD; Tiina M. Metso, MD, PhD; Turgut Tatlisumak, MD, PhD; Alessandro Pezzini, MD; Eugenio A. Parati, MD; Bo Norrving, MD, PhD; Steve Bevan, PhD; Peter M. Rothwell, MD, PhD, FRCP; Cathie Sudlow, DPhil, FRCP; Agnieszka Slowik, MD, PhD; Arne Lindgren, MD, PhD; Matthew R. Walters, MD; WTCCC-2 Consortium; Jim Jannes, PhD; Jess Shen, MSc; David Crosslin, PhD; Kimberly Doheny, PhD; Cathy C. Laurie, PhD; Sandip M. Kanse, PhD; Joshua C. Bis, PhD; Myriam Fornage, PhD; Thomas H. Mosley, PhD; Jemma C. Hopewell, PhD; Konstantin Strauch, PhD; Martina Müller-Nurasyid, MD, PhD; Christian Gieger, PhD; Melanie Waldenberger, PhD, MPH; Annette Peters, PhD; Christine Meisinger, MD; M. Arfan Ikram, MD, PhD; W.T. Longstreth Jr, MD, MPH; James F. Meschia, MD; Sudha Seshadri, MD; Pankaj Sharma, PhD, MD; Bradford Worrall, MD, MSc; Christina Jern, MD, PhD; Christopher Levi, MBBS; Martin Dichgans, MD; Giorgio B. Boncoraglio, MD; Hugh S. Markus, MD; Stephanie Debette, MD, PhD; Arndt Rolfs, MD; Danish Saleheen, MBBS, PhD; Braxton D. Mitchell, PhD Received August 27, 2015; final revision received November 6, 2015; accepted November 18, 2015.
    [Show full text]
  • HHS Public Access Author Manuscript
    HHS Public Access Author manuscript Author Manuscript Author ManuscriptMol Genet Author Manuscript Metab. Author Author Manuscript manuscript; available in PMC 2016 February 01. Published in final edited form as: Mol Genet Metab. 2015 February ; 114(2): 248–258. doi:10.1016/j.ymgme.2014.11.004. The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies Susana Ferreira1, Alberto Ortiz2, Dominique P. Germain3, Miguel Viana-Baptista4, António Caldeira Gomes5, Marta Camprecios6, Maria Fenollar-Cortés7, Ángel Gallegos-Villalobos8, Diego Garcia9, José Antonio García-Robles10, Jesús Egido11, Eduardo Gutiérrez-Rivas12, José Antonio Herrero13, Sebastián Mas14, Raluca Oancea15, Paloma Péres16, Luis Manuel Salazar-Martín17, Jesús Solera-Garcia18, Helena Alves19, Scott C. Garman20, and João Paulo Oliveira1,21,22 Susana Ferreira: [email protected]; Alberto Ortiz: [email protected]; Dominique P. Germain: [email protected]; Miguel Viana-Baptista: [email protected]; António Caldeira Gomes: [email protected]; Maria Fenollar-Cortés: [email protected]; Ángel Gallegos-Villalobos: [email protected]; Jesús Egido: [email protected]; Sebastián Mas: [email protected]; Helena Alves: [email protected]; Scott C. Garman: [email protected]; João Paulo Oliveira: [email protected] 1Departamento de Genética, Faculdade de Medicina, Universidade do Porto; 4200-319 Porto, Portugal 2Servicio de Nefrología, Instituto de Investigación Sanitaria
    [Show full text]
  • Fabry Disease: a Review of Current Management Strategies
    Revised submission June 2010 Fabry disease: a review of current management strategies A. MEHTA1, M. BECK2, F. EYSKENS3, C. FELICIANI4, I. KANTOLA5, U. RAMASWAMI6, A. ROLFS7, A. RIVERA8, S. WALDEK9, D.P. GERMAIN10 1Lysosomal Storage Disorders Unit, Department of Haematology, Royal Free Hospital and University College London School of Medicine, London, UK 2Children’s Hospital, University of Mainz, Mainz, Germany 3Department of Metabolic Diseases, ZNA Middelheim General Hospital, Antwerp, Belgium 4Department of Dermatology, Università Cattolica del Sacro Cuore, Rome, Italy 5Department of Medicine, Turku University Hospital, Turku, Finland 6Paediatric Metabolic Unit, Addenbrooke's Hospital, Cambridge, UK 7Albrecht-Kossel-Institute for Neuroregeneration, Medical Faculty, University of Rostock, Rostock, Germany 8Department of Internal Medicine, Complejo Hospitalario, Universitario de Vigo, Hospital Xeral de Vigo, Vigo, Spain 9Department of Adult Metabolic Diseases, Salford Royal NHS Foundation Trust, Salford, UK 10University of Versailles – St Quentin en Yvelines, Division of Medical Genetics, Hôpital Raymond Poincaré (AP-HP), 92380 Garches, France Corresponding author: Dr Atul Mehta, Lysosomal Storage Disorders Unit, Department of Academic Haematology, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK Tel: +44 (0) 20 7830 2814 Email: [email protected] Revised submission June 2010 Abstract Fabry disease is an X-linked inherited condition due to the absence or reduction of - galactosidase activity in lysosomes, that results in accumulation of globotriaosylceramide (Gb3) and related neutral glycosphingolipids. Manifestations of Fabry disease include serious and progressive impairment of renal and cardiac function. In addition, patients experience pain, gastrointestinal disturbance, transient ischaemic attacks and strokes. Additional effects on the skin, eyes, ears, lungs and bones are often seen.
    [Show full text]
  • Ischaemic Stroke in Young Adults: a Global Perspective
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2019-322424 on 3 February 2020. Downloaded from Cerebrovascular disease REVIEW Ischaemic stroke in young adults: a global perspective Esther Boot,1 Merel Sanne Ekker ,1 Jukka Putaala,2 Steven Kittner,3 Frank-­Erik De Leeuw,1 Anil M Tuladhar 1 ► Additional material is ABSTRact Furthermore, we will review the more traditional published online only. To view Ischaemic stroke at young age is an increasing problem vascular risk factors and geographical and racial/ please visit the journal online ethnic differences in their prevalence and strength (http:// dx. doi. org/ 10. 1136/ in both developing and developed countries due to jnnp- 2019- 322424). rising incidence, high morbidity and mortality and long- of association with stroke. term psychological, physical and social consequences. 1Department of Neurology, Compared with stroke in older adults, stroke in young METHODS Radboud Univerisity Medical adults is more heterogeneous due to the wide variety Centre, Donders Institute for For this review, we searched in MEDLINE and Brain, Cognition and Behaviour, of possible underlying risk factors and aetiologies. In WHO Database for articles published from 1 Centre for Neuroscience, this review, we will provide an overview of the global January 2008 to 1 January 2020. The following Nijmegen, The Netherlands variation in the epidemiology of stroke in young adults, 2 search terms (including MedicalSubject Headings) Department of Neurology, with special attention to differences in geography, Helsinki University Central were used in multiple combinations: ‘ischemic Hospital, Helsinki, Finland ethnicity/race and sex, as well as traditional and novel stroke, young adults, incidence, global, epidemi- 3 Department of Neurology, risk factors for early- onset ischaemic stroke, such ology, infection, sex differences, race, ethnicity, University of Maryland School of as air pollution.
    [Show full text]
  • Clinically Relevant Depressive Symptoms in Young Stroke Patients – Results of the Sifap1 Study
    Original Paper Neuroepidemiology 2015;44:30–38 Received: September 28, 2014 DOI: 10.1159/000371389 Accepted: December 4, 2014 Published online: January 31, 2015 Clinically Relevant Depressive Symptoms in Young Stroke Patients – Results of the sifap1 Study a b c, d c Christian Tanislav Peter Kropp Ulrike Grittner Martin Holzhausen e d f Franz Fazekas Gerhard Jan Jungehülsing Turgut Tatlisumak g f h i Bettina von Sarnowski Jukka Putaala Roman Huber Vincent Thijs e a e, j k Reinhold Schmidt Manfred Kaps Christian Enzinger Martin Dichgans l m Bo Norrving Arndt Rolfs a b Neurology, Justus Liebig University, Giessen , Institute of Medical Psychology and Medical Sociology, University c of Rostock, Rostock , Department for Biostatistics and Clinical Epidemiology, Charité-Universitätsmedizin Berlin, d e and Center for Stroke Research, Charité-Universitätsmedizin Berlin, Berlin , Germany; Department of Neurology, f Medical University of Graz, Graz , Austria; Department of Neurology, Helsinki University Central Hospital, g h Helsinki , Finland; Department of Neurology, University of Greifswald, Greifswald , Department of Neurology, i j Friedrichshafen , Germany; Clinical and Experimental Neurology, Leuven , Belgium; Department of Radiology, k Division of Neuroradiology, Medical University of Graz, Graz , Austria; Institute for Stroke and Dementia Research, l Klinikum Grosshadern, Munich , Germany; Department of Clinical Neuroscience, Neurology, Lund University, Lund , m Sweden; Albrecht-Kossel-Institute for Neuroregeneration, University of Rostock, Rostock , Germany Key Words relevant depressive symptoms (CRDS, defined by a BDI- Young stroke · Depression · Acute cerebral ischemia · score ≥ 18) the self-reporting Beck Depression Inventory sifap1 · Risk factors (BDI) was obtained on inclusion in the study. Associations with baseline parameters, stroke severity (National Institutes of Health Stroke Scale, NIHSS), and brain MRI findings were Abstract analyzed.
    [Show full text]
  • FOR OFFICIAL USE ONLY Public Disclosure Authorized Report No
    Document of The World Bank FOR OFFICIAL USE ONLY Public Disclosure Authorized Report No. 52691-MZ PROJECT APPRAISAL DOCUMENT ON A PROPOSED CREDIT Public Disclosure Authorized IN THE AMOUNT OF SDR 19.6 MILLION (US$30.4 MILLION EQUIVALENT) TO THE REPUBLIC OF MOZAMBIQUE FOR A NATIONAL DECENTRALIZED PLANNING AND FINANCE PROJECT Public Disclosure Authorized March 4,2010 Urban and Water Country Department AFCS2 Africa Region Public Disclosure Authorized This document has a restricted distribution and may be used by recipients only in the performance of their official duties. Its contents may not otherwise be disclosed without World Bank authorization. CURRENCY EQUIVALENTS (Exchange Rate Effective as January 3 1,201 0) Currency Unit = New Meticais (Mtn) 31.07Mtn = US$l US$1.55 = SDR1 FISCAL YEAR January 1 - December 31 ABBREVIATIONS AND ACRONYMS AD Administraqclo Distrital (District Administration) AT Assistzncia Te'cnica(Technical Assistance) AWPB Annual Work Plan and Budget BdPES Balanqo do Plano Econdmico Social (Monitoring System of the Annual Government Plan) CCD Conselho Consultivo Distrital (District Consultative Council) CdS Comite' de Supewisclo (Supervision Committee) CdSP Comite' de Supervisclo Provincial (Provincial Supervision Committee) CFAA Country Financial Accountability Assessment CFFM Common Fund Financing Mechanism CL Conselho Locais-CLs (Local Councils) CNCS Conselho Nacinal de Combate ao HIV/SIDA (National AIDS Council) CPAR Country Procurement Assessment Report CPS Country Partnership Strategy CQS Consultants' Qualification
    [Show full text]
  • Catalysing Ocean Finance
    Empowered lives. Resilient nations. Catalysing Ocean Finance Volume II Methodologies and Case Studies United Nations Development Programme Empowered lives. Resilient nations. UNDP partners with people at all levels of society to help build nations that can withstand crisis, and drive and sustain the kind of growth that improves the quality of life for everyone. On the ground in 177 countries and territories, we offer global perspective and local insight to help empower lives and build resilient nations. www.undp.org The GEF unites 182 countries in partnership with international institutions, non-governmental organizations (NGOs), and the private sector to address global environmental issues while supporting national sustainable development initiatives. Today the GEF is the largest public funder of projects to improve the global environment. An independently operating financial organization, the GEF provides grants for projects related to biodiversity, climate change, international waters, land degradation, the ozone layer, and persistent organic pollutants. Since 1991, GEF has achieved a strong track record with developing countries and countries with economies in transition, providing $9.2 billion in grants and leveraging $40 billion in co-financing for over 2,700 projects in over 168 countries. www.thegef.org September 2012 Catalysing Ocean Finance Volume II Methodologies and Case Studies Copyright © 2012 United Nations Development Programme United Nations Development Programme Global Environment Facility Bureau of Development Policy GEF Secretariat 304 East 45th Street , 1818 H Street, NW 9th Floor MSN P4-400 New York, NY 10017, USA Washington CD 20433, USA www.undp.org www.thegef.org All right reserved. This publication or parts of it may not be reproduced, stored by means of any system or transmitted, in any form or by any medium, whether electronic, mechanical, photocopied, recorded or of any other type, without the prior permission of the United Nations Development Programme.
    [Show full text]
  • Acute Cerebrovascular Disease in the Young the Stroke in Young Fabry Patients Study
    Acute Cerebrovascular Disease in the Young The Stroke in Young Fabry Patients Study Rolfs, Arndt; Fazekas, Franz; Grittner, Ulrike; Dichgans, Martin; Martus, Peter; Holzhausen, Martin; Boettcher, Tobias; Heuschmann, Peter U.; Tatlisumak, Turgut; Tanislav, Christian; Jungehulsing, Gerhard J.; Giese, Anne-Katrin; Putaala, Jukaa; Huber, Roman; Bodechtel, Ulf; Lichy, Christoph; Enzinger, Christian; Schmidt, Reinhold; Hennerici, Michael G.; Kaps, Manfred; Kessler, Christof; Lackner, Karl; Paschke, Eduard; Meyer, Wolfgang; Mascher, Hermann; Riess, Olaf; Kolodny, Edwin; Norrving, Bo Published in: Stroke: a journal of cerebral circulation DOI: 10.1161/STROKEAHA.112.663708 2013 Link to publication Citation for published version (APA): Rolfs, A., Fazekas, F., Grittner, U., Dichgans, M., Martus, P., Holzhausen, M., Boettcher, T., Heuschmann, P. U., Tatlisumak, T., Tanislav, C., Jungehulsing, G. J., Giese, A-K., Putaala, J., Huber, R., Bodechtel, U., Lichy, C., Enzinger, C., Schmidt, R., Hennerici, M. G., ... Norrving, B. (2013). Acute Cerebrovascular Disease in the Young The Stroke in Young Fabry Patients Study. Stroke: a journal of cerebral circulation, 44(2), 340-349. https://doi.org/10.1161/STROKEAHA.112.663708 Total number of authors: 28 General rights Unless other specific re-use rights are stated the following general rights apply: Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise
    [Show full text]
  • THE CONTRIBUTIONS of MARINE and COASTAL AREA-BASED MANAGEMENT APPROACHES to SUSTAINABLE DEVELOPMENT GOALS and TARGETS Supplementary Annex
    THE CONTRIBUTIONS OF MARINE AND COASTAL AREA-BASED MANAGEMENT APPROACHES TO SUSTAINABLE DEVELOPMENT GOALS AND TARGETS Supplementary Annex UN ENVIRONMENT REGIONAL SEAS REPORTS AND STUDIES NO. 205 Contents Introduction .................................................................................................................................................... 3 Case Study 1. Area of Particular Environmental Interest: Clarion-Clipperton Zone Areas of Particular Environmental Interest, Mid Pacific .............................................................................................................. 6 Case Study 2. Fisheries Closure and Conservation Area: Lyme Bay Reserve, United Kingdom ............... 16 Case Study 3. Integrated Coastal Zone Management: Coastal and Marine Spatial Planning in Belize ... 24 Case Study 4. Integrated Coastal Zone Management: Patagonian Coastal Zone Management Plan, Argentina ...................................................................................................................................................... 33 Case Study 5. Integrated Coastal Zone Management: Mediterranean Integrated Coastal Zone Management Protocol ................................................................................................................................. 43 Case Study 6. Large Marine Ecosystem: Bay of Bengal Large Marine Ecosystem Project (BOBLME)..... 54 Case Study 7. Locally Managed Marine Area: Madagascar Locally Managed Marine Area Network (MIHARI) ......................................................................................................................................................
    [Show full text]